A novel controlled local drug delivery system for inner ear disease

David P. Paulson, Waleed M. Abuzeid, Hao Jiang, Tomoyuki Oe, Bert W. O'Malley, Daqing Li

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

PURPOSE: Our goal is to develop a novel drug delivery system that can potentially improve clinical outcomes compared to current methods of dosing drugs such as dexamethasone or gentamicin. This system focuses on a single local application to the inner ear via the round window membrane. HYPOTHESIS: A chitosan-glycerophosphate (CGP)-hydrogel based drug delivery system can be engineered to provide local and sustained drug release to the inner ear. STUDY DESIGN: In vitro: drug release and (CGP)-hydrogel matrix degradation were characterized using dexamethasone as a model drug. In vivo: dexamethasone laden CGP-hydrogel was placed in the round window niche of mice. Perilymph samples were obtained from the oval window and analyzed for dexamethasone. The impact of CGP-hydrogel on auditory function was evaluated. RESULTS: In vitro: A CGP-hydrogel was designed to release 92% of the dexamethasone load over 4 consecutive days with concurrent degradation of the hydrogel matrix. In vivo: After surgical placement of CGP-hydrogel to the round window niche, we detected elevated levels of dexamethasone in perilymph for 5 days. Auditory function testing revealed a temporary hearing loss in the immediate postoperative period, which resolved by the 10th postoperative day. CONCLUSIONS: We report the development of CGP-hydrogel, a biodegradable matrix that achieves local, sustained delivery of dexamethasone to the inner ear. There were no significant complications resulting from the surgical procedure or the administration of CGP-hydrogel to our murine model.

Original languageEnglish (US)
Pages (from-to)706-711
Number of pages6
JournalLaryngoscope
Volume118
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Labyrinth Diseases
Glycerophosphates
Hydrogel
Drug Delivery Systems
Chitosan
Dexamethasone
Inner Ear
Perilymph
Ear Round Window
Gentamicins
Hearing Loss
Postoperative Period
Pharmaceutical Preparations

Keywords

  • C57
  • Chitosan glycerophosphate
  • Dexamethasone
  • Drug delivery
  • Ear
  • Hydrogel
  • Mouse
  • Perilymph analysis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

A novel controlled local drug delivery system for inner ear disease. / Paulson, David P.; Abuzeid, Waleed M.; Jiang, Hao; Oe, Tomoyuki; O'Malley, Bert W.; Li, Daqing.

In: Laryngoscope, Vol. 118, No. 4, 04.2008, p. 706-711.

Research output: Contribution to journalArticle

Paulson, DP, Abuzeid, WM, Jiang, H, Oe, T, O'Malley, BW & Li, D 2008, 'A novel controlled local drug delivery system for inner ear disease', Laryngoscope, vol. 118, no. 4, pp. 706-711. https://doi.org/10.1097/MLG.0b013e31815f8e41
Paulson, David P. ; Abuzeid, Waleed M. ; Jiang, Hao ; Oe, Tomoyuki ; O'Malley, Bert W. ; Li, Daqing. / A novel controlled local drug delivery system for inner ear disease. In: Laryngoscope. 2008 ; Vol. 118, No. 4. pp. 706-711.
@article{7a2b907741244e08b8268857436a16bb,
title = "A novel controlled local drug delivery system for inner ear disease",
abstract = "PURPOSE: Our goal is to develop a novel drug delivery system that can potentially improve clinical outcomes compared to current methods of dosing drugs such as dexamethasone or gentamicin. This system focuses on a single local application to the inner ear via the round window membrane. HYPOTHESIS: A chitosan-glycerophosphate (CGP)-hydrogel based drug delivery system can be engineered to provide local and sustained drug release to the inner ear. STUDY DESIGN: In vitro: drug release and (CGP)-hydrogel matrix degradation were characterized using dexamethasone as a model drug. In vivo: dexamethasone laden CGP-hydrogel was placed in the round window niche of mice. Perilymph samples were obtained from the oval window and analyzed for dexamethasone. The impact of CGP-hydrogel on auditory function was evaluated. RESULTS: In vitro: A CGP-hydrogel was designed to release 92{\%} of the dexamethasone load over 4 consecutive days with concurrent degradation of the hydrogel matrix. In vivo: After surgical placement of CGP-hydrogel to the round window niche, we detected elevated levels of dexamethasone in perilymph for 5 days. Auditory function testing revealed a temporary hearing loss in the immediate postoperative period, which resolved by the 10th postoperative day. CONCLUSIONS: We report the development of CGP-hydrogel, a biodegradable matrix that achieves local, sustained delivery of dexamethasone to the inner ear. There were no significant complications resulting from the surgical procedure or the administration of CGP-hydrogel to our murine model.",
keywords = "C57, Chitosan glycerophosphate, Dexamethasone, Drug delivery, Ear, Hydrogel, Mouse, Perilymph analysis",
author = "Paulson, {David P.} and Abuzeid, {Waleed M.} and Hao Jiang and Tomoyuki Oe and O'Malley, {Bert W.} and Daqing Li",
year = "2008",
month = "4",
doi = "10.1097/MLG.0b013e31815f8e41",
language = "English (US)",
volume = "118",
pages = "706--711",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - A novel controlled local drug delivery system for inner ear disease

AU - Paulson, David P.

AU - Abuzeid, Waleed M.

AU - Jiang, Hao

AU - Oe, Tomoyuki

AU - O'Malley, Bert W.

AU - Li, Daqing

PY - 2008/4

Y1 - 2008/4

N2 - PURPOSE: Our goal is to develop a novel drug delivery system that can potentially improve clinical outcomes compared to current methods of dosing drugs such as dexamethasone or gentamicin. This system focuses on a single local application to the inner ear via the round window membrane. HYPOTHESIS: A chitosan-glycerophosphate (CGP)-hydrogel based drug delivery system can be engineered to provide local and sustained drug release to the inner ear. STUDY DESIGN: In vitro: drug release and (CGP)-hydrogel matrix degradation were characterized using dexamethasone as a model drug. In vivo: dexamethasone laden CGP-hydrogel was placed in the round window niche of mice. Perilymph samples were obtained from the oval window and analyzed for dexamethasone. The impact of CGP-hydrogel on auditory function was evaluated. RESULTS: In vitro: A CGP-hydrogel was designed to release 92% of the dexamethasone load over 4 consecutive days with concurrent degradation of the hydrogel matrix. In vivo: After surgical placement of CGP-hydrogel to the round window niche, we detected elevated levels of dexamethasone in perilymph for 5 days. Auditory function testing revealed a temporary hearing loss in the immediate postoperative period, which resolved by the 10th postoperative day. CONCLUSIONS: We report the development of CGP-hydrogel, a biodegradable matrix that achieves local, sustained delivery of dexamethasone to the inner ear. There were no significant complications resulting from the surgical procedure or the administration of CGP-hydrogel to our murine model.

AB - PURPOSE: Our goal is to develop a novel drug delivery system that can potentially improve clinical outcomes compared to current methods of dosing drugs such as dexamethasone or gentamicin. This system focuses on a single local application to the inner ear via the round window membrane. HYPOTHESIS: A chitosan-glycerophosphate (CGP)-hydrogel based drug delivery system can be engineered to provide local and sustained drug release to the inner ear. STUDY DESIGN: In vitro: drug release and (CGP)-hydrogel matrix degradation were characterized using dexamethasone as a model drug. In vivo: dexamethasone laden CGP-hydrogel was placed in the round window niche of mice. Perilymph samples were obtained from the oval window and analyzed for dexamethasone. The impact of CGP-hydrogel on auditory function was evaluated. RESULTS: In vitro: A CGP-hydrogel was designed to release 92% of the dexamethasone load over 4 consecutive days with concurrent degradation of the hydrogel matrix. In vivo: After surgical placement of CGP-hydrogel to the round window niche, we detected elevated levels of dexamethasone in perilymph for 5 days. Auditory function testing revealed a temporary hearing loss in the immediate postoperative period, which resolved by the 10th postoperative day. CONCLUSIONS: We report the development of CGP-hydrogel, a biodegradable matrix that achieves local, sustained delivery of dexamethasone to the inner ear. There were no significant complications resulting from the surgical procedure or the administration of CGP-hydrogel to our murine model.

KW - C57

KW - Chitosan glycerophosphate

KW - Dexamethasone

KW - Drug delivery

KW - Ear

KW - Hydrogel

KW - Mouse

KW - Perilymph analysis

UR - http://www.scopus.com/inward/record.url?scp=41849096031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849096031&partnerID=8YFLogxK

U2 - 10.1097/MLG.0b013e31815f8e41

DO - 10.1097/MLG.0b013e31815f8e41

M3 - Article

VL - 118

SP - 706

EP - 711

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 4

ER -